Download Spot the hidden danger

HOW THE T-SPOT.TB TEST IS USED
Preventative screening amongst immunocompromised
patient groups including:
HIV, anti-TNFα, cancer chemotherapy, renal dialysis and transplant patients
Targeted testing of high risk populations including:
TB suspects, close contacts, immigrants, prisons, care-homes
Pre-employment and regular screening of key professions:
Healthcare professionals/occupational health
T-SPOT.TB Test Advantages at a Glance
Single blood sample. No repeat visit
Unaffected by BCG vaccination and common non-tuberculous
mycobacteria
Unrivalled sensitivity, maintained even in the immunocompromised
A cost-effective model for TB control
The blood test for the detection of
latent infection and TB disease.
Antigens licensed from
Statens Serum Institut
Denmark
LP-TB-UK-V8
Contact Oxford Immunotec for further information.
T-SPOT® and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
© Oxford Immunotec Ltd. 2013 All rights reserved. www.oxfordimmunotec.com
Oxford Immunotec Limited, 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK
Tel: +44 (0)1235 442780 Fax: +44 (0)1235 442781 Email: [email protected]
Spot the hidden danger
HOW THE T-SPOT®.TB TEST HELPS YOU
HOW THE T-SPOT.TB TEST WORKS
The T-SPOT.
test gives you accurate results in all patient
groups, time after time with minimum effort
Sensitivity
The T-SPOT.TB test has a sensitivity of 95.6%1 which is maintained even in the
immunocompromised2, 3 including HIV infected subjects4. Compared to other assays,
the T-SPOT.TB test identifies a higher percentage of infected subjects and can be used to
help rule-out active disease in TB suspects in just 24 hours.
Specificity
The T-SPOT.TB test uses the RD1 antigens, ESAT-6 and CFP10, which ensure it does not cross
react with the BCG vaccine or most environmental mycobacteria5, 6. Since the specificity of
the T-SPOT.TB test is 97.1%7, false positives are rare so unnecessary chemoprophylaxis
and follow-up is avoided.
Simplicity
The T-SPOT.TB test requires a single blood sample so only one visit is required. Blood can be
collected in Vacutainer®, Cell Preparation Tubes or any readily available lithium heparin blood tube.
Cost-effectiveness
As the T-SPOT.TB test dramatically reduces the number of false positive and false negative
results, it helps ensure that therapy is targeted at people who are truly infected8,9.
1.
2.
3.
4.
5.
T-SPOT.TB Pivotal Clinical Trial (PI-TB-US-V1)
Meier T. el al. Eur J Clin Microbiol Infect Dis 24: 529–536, 2005
Lee JY. et al. Eur Respir J 2006; 28: 24–30
Clarke S. et al. Clin Exp Immunol 2007 150(2):238-44
Adams L et al. Scandinavian Journal of Infectious Diseases.
2008, 1-8
6.
7.
8.
9.
van Leeuwen R et al. Eur Respir J 2007; 29: 605–607
T-SPOT.TB Pivotal Clinical Trial (PI-TB-US-V1)
Wrighton-Smith P. et al. Eur Respir J 2006; 28: 45–50
Diel R. et al. ERJ 2007 30: 321-332
For full technical details visit www.oxfordimmunotec.com